IPSEN (IPSEY) – What Are Researchers Thinking About This Stock?

IPSEN (OTCMKTS:IPSEY) has earned a consensus rating of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company.

A number of equities analysts have recently issued reports on the company. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th.

IPSEN Stock Performance

Shares of IPSEY opened at $43.00 on Friday. IPSEN has a twelve month low of $34.34 and a twelve month high of $51.10. The company has a 50 day moving average of $44.38 and a two-hundred day moving average of $46.03.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.